IBEX 35
11.125,20 +75,10 (+0,68%) Euro Stoxx 50
5.090,65 +36,24 (+0,72%) Dólar/Euro
1,0770 -0,0014 (-0,13%) Petróleo Brent
84,24 +0,36 (+0,43%) Oro
2.371,70 +31,40 (+1,34%) Bitcoin EUR
58.695,38 +1.631,25 (+2,86%)
Oncternal Therapeutics, Inc. (ONCT)
Después del cierre:
Oncternal Therapeutics, Inc.
12230 El Camino Real
Suite 230
San Diego, CA 92130
United States
858 434 1113
https://www.oncternal.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 27
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. James B. Breitmeyer M.D., Ph.D. | President, CEO & Director | 881,36k | N/A | 1954 |
| Mr. Richard G. Vincent CPA | CFO & Treasurer | 602,84k | N/A | 1964 |
| Dr. Salim Yazji M.D. | Chief Medical Officer | 648,53k | N/A | 1969 |
| Dr. Rajesh Krishnan Ph.D. | Chief Technical & Scientific Officer | N/A | N/A | 1973 |
| Mr. Chase C. Leavitt | General Counsel & Secretary | N/A | N/A | 1982 |
| Mr. Pablo Urbaneja | Senior Vice President of Corporate Development | N/A | N/A | N/A |
| Ms. Anita Wiseth | Senior Vice President of Human Resources | N/A | N/A | N/A |
Descripción
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.
Gobierno corporativo
El ISS Governance QualityScore de Oncternal Therapeutics, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
